TYK2 inhibitor

Blocks IL-23 and type I interferon signaling — psoriasis
Allosteric selectivity spares JAK1 and JAK2

Drugs with this mechanism (1)

Deucravacitinib — Selective allosteric TYK2 inhibitor for plaque psoriasis; lacks the JAK class boxed warning.

All mechanisms · Open the interactive console ↗